Literature DB >> 22653557

Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis.

Laura A Bienvenu1, James Morgan, Amanda J Rickard, Greg H Tesch, Greg A Cranston, Elizabeth K Fletcher, Lea M D Delbridge, Morag J Young.   

Abstract

Mineralocorticoid receptor (MR) activation promotes the development of cardiac fibrosis and heart failure. Clinical evidence demonstrates that MR antagonism is protective even when plasma aldosterone levels are not increased. We hypothesize that MR activation in macrophages drives the profibrotic phenotype in the heart even when aldosterone levels are not elevated. The aim of the present study was to establish the role of macrophage MR signaling in mediating cardiac tissue remodeling caused by nitric oxide (NO) deficiency, a mineralocorticoid-independent insult. Male wild-type (MRflox/flox) and macrophage MR-knockout (MRflox/flox/LysMCre/+; mac-MRKO) mice were uninephrectomized, maintained on 0.9% NaCl drinking solution, with either vehicle (control) or the nitric oxide synthase (NOS) inhibitor NG-nitro-l-arginine methyl ester (L-NAME; 150 mg/kg/d) for 8 wk. NO deficiency increased systolic blood pressure at 4 wk in wild-type L-NAME/salt-treated mice compared with all other groups. At 8 wk, systolic blood pressure was increased above control in both L-NAME/salt treated wild-type and mac-MRKO mice by approximately 28 mm Hg by L-NAME/salt. Recruitment of macrophages was increased 2- to 3-fold in both L-NAME/salt treated wild-type and mac-MRKO. Inducible NOS positive macrophage infiltration and TNFα mRNA expression was greater in wild-type L-NAME/salt-treated mice compared with mac-MRKO, demonstrating that loss of MR reduces M1 phenotype. mRNA levels for markers of vascular inflammation and oxidative stress (NADPH oxidase 2, p22phox, intercellular adhesion molecule-1, G protein-coupled chemokine receptor 5) were similar in treated wild-type and mac-MRKO mice compared with control groups. In contrast, L-NAME/salt treatment increased interstitial collagen deposition in wild-type by about 33% but not in mac-MRKO mice. mRNA levels for connective tissue growth factor and collagen III were also increased above control treatment in wild-type (1.931 ± 0.215 vs. 1 ± 0.073) but not mac-MRKO mice (1.403 ± 0.150 vs. 1.286 ± 0.255). These data demonstrate that macrophage MR are necessary for the translation of inflammation and oxidative stress into interstitial and perivascular fibrosis after NO deficiency, even when plasma aldosterone is not elevated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653557     DOI: 10.1210/en.2011-2098

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  45 in total

1.  Essential role of ICAM-1 in aldosterone-induced atherosclerosis.

Authors:  Vincenzo Marzolla; Andrea Armani; Caterina Mammi; Mary E Moss; Vittoria Pagliarini; Laura Pontecorvo; Antonella Antelmi; Andrea Fabbri; Giuseppe Rosano; Iris Z Jaffe; Massimiliano Caprio
Journal:  Int J Cardiol       Date:  2017-01-05       Impact factor: 4.164

2.  Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

Authors:  Margarita Pizarro; Nancy Solís; Pablo Quintero; Francisco Barrera; Daniel Cabrera; Pamela Rojas-de Santiago; Juan P Arab; Oslando Padilla; Juan C Roa; Han Moshage; Alexander Wree; Eugenia Inzaugarat; Ariel E Feldstein; Carlos E Fardella; Rene Baudrand; Arnoldo Riquelme; Marco Arrese
Journal:  Liver Int       Date:  2015-02-23       Impact factor: 5.828

Review 3.  Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Authors:  Nicholas C Bene; Pilar Alcaide; Henry H Wortis; Iris Z Jaffe
Journal:  Steroids       Date:  2014-04-21       Impact factor: 2.668

Review 4.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 5.  Cardiac myocyte-fibroblast interactions and the coronary vasculature.

Authors:  Stephanie L K Bowers; Troy A Baudino
Journal:  J Cardiovasc Transl Res       Date:  2012-09-18       Impact factor: 4.132

Review 6.  Overnutrition, mTOR signaling, and cardiovascular diseases.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-24       Impact factor: 3.619

Review 7.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 8.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 9.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 10.  Aldosterone in vascular and metabolic dysfunction.

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.